FEATURED PRODUCT CATEGORIES
ADVANCING THE FUTURE OF CANCER TREATMENT
At ichorbio, we understand that developing the next breakthrough therapy requires reliable tools and scalable solutions. Our comprehensive range of research biosimilars and in vivo antibodies supports your journey from initial screening through preclinical development, helping you validate targets and accelerate your pipeline with confidence.
Ready to accelerate your development pipeline?
NEW PRODUCTS
View MoreCITATIONS
Latest Publications Featuring ichorbio Products
Your Partner in Development
From early-stage research through preclinical development, ichorbio provides the tools and support you need to advance your pipeline. Our commitment to quality, comprehensive documentation, and reliable bulk supply helps accelerate your journey from innovative concept to breakthrough therapy.
-
Posted: August 07, 2025Categories: Antibodies in Clinic / Clinical Trials
FDA Approval Spotlight: Linvoseltamab — A BCMA x CD3 Bispecific for Multiple Myeloma
In July 2025, the FDA granted accelerated approval to linvoseltamab, a BCMA × CD3 T-cell engaging bispecific antibody, for the treatment of ...
-
Posted: July 28, 2025Categories: ichorbio Citations (Resources)
Oncolytic Virus Expressing Non-Secreted DR-18 Cytokine Induces Potent, Systemic Antitumor Immunity
A recent study published in
Molecular Therapy: Oncology (Vol. 33, Sept 2025) demonstrates the therapeutic potential of a novel oncolytic vaccinia...
-
Posted: July 07, 2025Categories: ichorbio Citations (Resources)